Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.105 USD | +0.81% | -12.78% | +151.20% |
05-08 | Lexaria Bioscience Corp. Begins Dosing of Its Second Glp-1 Human Pilot Study | CI |
04-16 | Lexaria Obtains Ethics Review Board Approval to Start New GLP-1 Study | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+151.20% | 39.69M | |
+32.85% | 709B | |
+30.77% | 595B | |
-2.44% | 367B | |
+20.03% | 334B | |
+4.99% | 289B | |
+14.28% | 239B | |
+9.08% | 211B | |
-3.84% | 203B | |
+8.80% | 171B |
- Stock Market
- Equities
- LEXX Stock
- News Lexaria Bioscience Corp.
- Lexaria Bioscience Granted Two Canadian Patents for Nicotine Addiction Treatment Candidate